![shutterstock_2658171737 [Converted]_Smaller.jpg](https://static.wixstatic.com/media/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg/v1/fill/w_147,h_49,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg)
Member Spotlight
Trevor Ambron, PA-C
Trevor Ambron, PA-C, is a U.S. Air Force–trained physician assistant with a remarkable career spanning frontline military medicine, presidential-level care, and advanced interventional pain management. From deployments in Afghanistan and Iraq to serving in the White House Medical Unit, he has delivered high-level care in some of the most demanding environments. Now a leader in interventional pain medicine, he specializes in minimally invasive, image-guided treatments that restore function and improve quality of life.
.png)
EARLY BIRD REGISTRATION ENDS SEPTEMBER 1!
INDUSTRY NEWS
Will recent FDA approval of a novel
nonopioid analgesic be a game changer?
Physician's Weekly
The Food and Drug Administration recently approved Journavx, a first-in-class oral, nonopioid, highly selective sodium channel blocker indicated as a treatment for adults with moderate to severe acute pain. Clinical data revealed that this agent is an effective, well-tolerated medicine without evidence of addictive potential, indicated for use with all types of moderate to sever acute pain.
